105 related articles for article (PubMed ID: 33159706)
1. Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population.
Sato J; Azuma K; Kinowaki K; Ikeda K; Ogura T; Takazawa Y; Kawabata H; Kitagawa M; Inoue S
Pathol Int; 2021 Jan; 71(1):60-69. PubMed ID: 33159706
[TBL] [Abstract][Full Text] [Related]
2. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
[TBL] [Abstract][Full Text] [Related]
3. Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis.
Xiao G; Yang Q; Bao Z; Mao H; Zhang Y; Lin S
BMC Cancer; 2020 Jun; 20(1):525. PubMed ID: 32503466
[TBL] [Abstract][Full Text] [Related]
4. High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer.
Liu S; Meng F; Ding J; Ji H; Lin M; Zhu J; Ma R
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30792262
[TBL] [Abstract][Full Text] [Related]
5. Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma.
Wu J; Guo NZ; Cui LL; Wang W; Xiong CQ; Zhang XY
Medicine (Baltimore); 2018 Nov; 97(44):e13021. PubMed ID: 30383661
[TBL] [Abstract][Full Text] [Related]
6. Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer.
Sato J; Azuma K; Kinowaki K; Ikeda K; Ogura T; Takazawa Y; Kawabata H; Kitagawa M; Inoue S
Clin Breast Cancer; 2021 Oct; 21(5):399-407.e2. PubMed ID: 33386231
[TBL] [Abstract][Full Text] [Related]
7. The Novel Target of Colorectal Carcinoma: TRIM44 Regulates Cell Migration and Invasion via Activation of CXCR4/NF-κB Signaling.
Kou T; Sha D; Wang F; He T; He X
Cell Biochem Biophys; 2021 Mar; 79(1):113-121. PubMed ID: 33151473
[TBL] [Abstract][Full Text] [Related]
8. Tripartite Motif-Containing 44 is Involved in the Tumorigenesis of Laryngeal Squamous Cell Carcinoma, and its Expression is Downregulated by Nuciferine.
Li QH; Sui LP; Zhao YH; Chen BG; Li J; Ma ZH; Hu ZH; Tang YL; Guo YX
Tohoku J Exp Med; 2021 May; 254(1):17-23. PubMed ID: 34011804
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer.
Liu S; Yin H; Ji H; Zhu J; Ma R
Exp Ther Med; 2018 Oct; 16(4):3034-3040. PubMed ID: 30214522
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of TRIM44 Expression in Patients with Gastric Cancer.
Goshayeshi L; Afshar J; Mehrad-Majd H
Asian Pac J Cancer Prev; 2022 May; 23(5):1725-1731. PubMed ID: 35633558
[TBL] [Abstract][Full Text] [Related]
11. A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor.
Yamada Y; Takayama KI; Fujimura T; Ashikari D; Obinata D; Takahashi S; Ikeda K; Kakutani S; Urano T; Fukuhara H; Homma Y; Inoue S
Cancer Sci; 2017 Jan; 108(1):32-41. PubMed ID: 27754579
[TBL] [Abstract][Full Text] [Related]
12. Expression of TRIM44 and its correlation with TLR4 in laryngeal squamous cell carcinoma.
Bai J; Liu X; Zhang S; Dang S; Zhang Y; Zhang G
Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):56-61. PubMed ID: 36227676
[TBL] [Abstract][Full Text] [Related]
13. Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy.
Ong CA; Shannon NB; Ross-Innes CS; O'Donovan M; Rueda OM; Hu DE; Kettunen MI; Walker CE; Noorani A; Hardwick RH; Caldas C; Brindle K; Fitzgerald RC
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777112
[TBL] [Abstract][Full Text] [Related]
14. TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma.
Yamada Y; Kimura N; Takayama KI; Sato Y; Suzuki T; Azuma K; Fujimura T; Ikeda K; Kume H; Inoue S
Cancer Sci; 2020 Mar; 111(3):881-890. PubMed ID: 31883420
[TBL] [Abstract][Full Text] [Related]
15. High TRIM44 expression in endometrial carcinoma is associated with a poorer patient outcome.
Li P; Yin H; Meng F; Liu S; Liu H; Ma R
Pathol Res Pract; 2018 May; 214(5):727-731. PubMed ID: 29526558
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Assessment of TNFAIP3/A20 Expression Correlates With Early Tumorigenesis in Breast Cancer.
Sharif-Askari FS; Al-Khayyal N; Talaat I; Sharif-Askari NS; Rawat S; Jundi M; SyrjÄnen K; Hamoudi R; Bendardaf R
Anticancer Res; 2021 Feb; 41(2):739-745. PubMed ID: 33517278
[TBL] [Abstract][Full Text] [Related]
17. TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway.
Xiong D; Jin C; Ye X; Qiu B; Jianjun X; Zhu S; Xiang L; Wu H; Yongbing W
Cancer Sci; 2018 Oct; 109(10):3080-3092. PubMed ID: 30098109
[TBL] [Abstract][Full Text] [Related]
18. Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway.
Luo Q; Lin H; Ye X; Huang J; Lu S; Xu L
Int J Clin Oncol; 2015 Jun; 20(3):508-17. PubMed ID: 25345539
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of long non-coding RNA DUXAP8 suppresses proliferation, metastasis and EMT by modulating miR-498 through TRIM44-mediated AKT/mTOR pathway in non-small-cell lung cancer.
Ji X; Tao R; Sun LY; Xu XL; Ling W
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3152-3165. PubMed ID: 32271433
[TBL] [Abstract][Full Text] [Related]
20. TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.
Wei CY; Wang L; Zhu MX; Deng XY; Wang DH; Zhang SM; Ying JH; Yuan X; Wang Q; Xuan TF; He AQ; Qi FZ; Gu JY
J Exp Clin Cancer Res; 2019 Mar; 38(1):137. PubMed ID: 30922374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
